Stanford MD: The Longevity Industry Is Lying To You

Longevity science is advancing quickly. Healthcare systems are moving much slower.

In this episode, Stanford-trained physician Dr. Hillary Lin explains why prevention, biological age testing, mitochondria, and health optimization often struggle to translate into real clinical practice. We discuss the limits of NAD+ supplementation, the risks around peptides, and why behavioral change still drives most health outcomes.

The conversation also looks at decentralizing healthcare, continuous monitoring, and why many high performers struggle with recovery despite doing “everything right.”

What you’ll learn

• Why longevity science and healthcare are misaligned
• The role mitochondria play in aging and energy
• When NAD+ supplementation can backfire
• Risks around peptides and self-experimentation
• Why behavior change drives most longevity gains
• The future of continuous health monitoring

Topics

00:00 The gap in longevity care
02:17 Hillary Lin’s path into longevity medicine
05:28 Decentralizing healthcare
08:13 Mental health navigation
14:05 Mitochondria and mitophagy
16:45 The NAD+ problem
22:33 High performer bottlenecks
27:20 Behavior change and longevity
30:31 Peptides in longevity medicine
35:02 Continuous healthcare models
46:19 Biological age testing
51:32 The future of healthcare monitoring

Follow Hillary:

https://www.hillarylinmd.com/

https://www.linkedin.com/in/hillarylinmd/

https://www.instagram.com/hillarylinmd/?hl=en

More about Return on Health:

⁠https://returnonhealth.de/⁠

Niko:

⁠https://www.linkedin.com/in/niko-hems/⁠

⁠https://www.instagram.com/niko_hems⁠

⁠https://nikohems.de/⁠

Miguel:

⁠https://www.linkedin.com/in/miguel-medina-stanivukovic-857b9720b/⁠

⁠https://www.instagram.com/miguelmedinastanivukovic/?hl=en